Stefan Müllner
Plus aucun poste en cours
Profil
Stefan Müllner is the founder of Warburg-Glycomed GmbH (founded in 2007) and Protagen AG (founded in 1997).
At Protagen AG, he held the title of Chief Executive Officer from 2009 to 2011.
Dr. Müllner's former jobs include Chief Executive Officer at fundamenta CAPITAL AG, Director-Enzyme Technology at Henkel AG & Co. KGaA, Head-Biotechnology & Corporate Research at Hoechst AG, and Principal at Aventis SA.
Anciens postes connus de Stefan Müllner
| Sociétés | Poste | Fin |
|---|---|---|
| HENKEL AG & CO. KGAA | Corporate Officer/Principal | - |
Warburg-Glycomed GmbH
 Warburg-Glycomed GmbH Medical DistributorsDistribution Services Warburg-Glycomed GmbH is a biopharmaceutical company focused on the discovery and development of small molecule oncology drugs. The drug development platform of Warburg-Glycomed GmbH builds on profound know-how in cell energy metabolism, enzymology and signal transduction pathways of tumor cells and their translation into new classes of oncology drugs. The company was founded on October 1, 2007 and is headquartered in Erkrath, Germany. | Fondateur | - |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Corporate Officer/Principal | - |
Aventis SA
 Aventis SA Pharmaceuticals: MajorHealth Technology Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France. | Corporate Officer/Principal | - |
Protagen AG
 Protagen AG BiotechnologyHealth Technology Protagen AG specializes in the development of novel diagnostic and companion diagnostic tests. Its products and services include GMP analyses, protein identification and analyses, proteome studies, UNIchip, clone and array, Bio-IT, Modiro as well as ProteinScape and Solver. The company was founded by Stefan Müllner, Helmut E. Meyer, Petra Weingarten and Martin Blüggel in 1997 and is headquartered in Dortmund, Germany. | Directeur Général | - |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HENKEL AG & CO. KGAA | Consumer Non-Durables |
| Entreprise privées | 5 |
|---|---|
fundamenta CAPITAL AG
 fundamenta CAPITAL AG Investment ManagersFinance fundamenta CAPITAL AG (fundamenta) is the financial services subsidiary of K + R Beteiligungs GmbH in Germany. Established in 1998, the firm supports biotech companies during the strategic preparation and carrying out of the second and third rounds of financing as well as with the acquisition and development of industry co-operations. They are headquartered in Bergisch Gladbach, Germany. | Finance |
Protagen AG
Protagen AG BiotechnologyHealth Technology Protagen AG specializes in the development of novel diagnostic and companion diagnostic tests. Its products and services include GMP analyses, protein identification and analyses, proteome studies, UNIchip, clone and array, Bio-IT, Modiro as well as ProteinScape and Solver. The company was founded by Stefan Müllner, Helmut E. Meyer, Petra Weingarten and Martin Blüggel in 1997 and is headquartered in Dortmund, Germany. | Health Technology |
Aventis SA
Aventis SA Pharmaceuticals: MajorHealth Technology Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France. | Health Technology |
Hoechst AG
Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Warburg-Glycomed GmbH
Warburg-Glycomed GmbH Medical DistributorsDistribution Services Warburg-Glycomed GmbH is a biopharmaceutical company focused on the discovery and development of small molecule oncology drugs. The drug development platform of Warburg-Glycomed GmbH builds on profound know-how in cell energy metabolism, enzymology and signal transduction pathways of tumor cells and their translation into new classes of oncology drugs. The company was founded on October 1, 2007 and is headquartered in Erkrath, Germany. | Distribution Services |
